75 related articles for article (PubMed ID: 10959302)
1. [Gliadel--a preparation for the supplementary treatment of brain cancer].
Domb A
Harefuah; 1999 Aug; 137(3-4):127-31. PubMed ID: 10959302
[No Abstract] [Full Text] [Related]
2. Gliadel wafers for treatment of brain tumors.
Med Lett Drugs Ther; 1998 Sep; 40(1035):92. PubMed ID: 9760950
[No Abstract] [Full Text] [Related]
3. [Local chemotherapy of malignant glioma: from syringe injections to nanotechnology].
Petit S; Garcion E; Benoit JP; Menei P
Rev Neurol (Paris); 2008; 164(6-7):547-53. PubMed ID: 18565353
[TBL] [Abstract][Full Text] [Related]
4. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.
Broggi G; Ferroli P; Franzini A; Silvani A; Salmaggi A; Eoli M; Boiardi A
J Neurosurg; 2003 Apr; 98(4):935-6; author reply 936. PubMed ID: 12691429
[No Abstract] [Full Text] [Related]
5. Drug delivery to brain tumours: challenges and progress.
Ningaraj NS
Expert Opin Drug Deliv; 2006 Jul; 3(4):499-509. PubMed ID: 16822225
[TBL] [Abstract][Full Text] [Related]
6. Editors' remarks: Evolving concepts for local therapies for glioma.
Westphal M; Tonn JC
Acta Neurochir Suppl; 2003; 88():VII-IX. PubMed ID: 14531552
[No Abstract] [Full Text] [Related]
7. Blood-brain barrier and chemotherapeutic treatment of brain tumors.
de Vries NA; Beijnen JH; Boogerd W; van Tellingen O
Expert Rev Neurother; 2006 Aug; 6(8):1199-209. PubMed ID: 16893347
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Abrey LE; Ferrari N; Hall WA; Laws ER; McLendon RE; Muldoon LL; Peereboom D; Peterson DR; Reynolds CP; Senter P; Neuwelt EA
Clin Cancer Res; 2002 Jun; 8(6):1702-9. PubMed ID: 12060607
[TBL] [Abstract][Full Text] [Related]
9. [Brain tumors].
Brihaye J; Gueuning C; Huysman E
Acta Chir Belg; 1971; Suppl 1():Suppl 1:42-59. PubMed ID: 5561314
[No Abstract] [Full Text] [Related]
10. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
[TBL] [Abstract][Full Text] [Related]
11. [Temporary hyperosmolar breakage of the blood-brain barrier improves effectiveness of chemotherapy for cerebral tumors].
Aronov MS; Kobiakov GL; Lubnin AIu; Iakovlev SB
Zh Vopr Neirokhir Im N N Burdenko; 2008; (3):52-9. PubMed ID: 19062597
[No Abstract] [Full Text] [Related]
12. Chemotherapy and the treatment of brain metastases.
Peak S; Abrey LE
Hematol Oncol Clin North Am; 2006 Dec; 20(6):1287-95. PubMed ID: 17113463
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for brain tumours.
Lesniak MS; Brem H
Nat Rev Drug Discov; 2004 Jun; 3(6):499-508. PubMed ID: 15173839
[No Abstract] [Full Text] [Related]
14. Use of nanoparticles for drug delivery in glioblastoma multiforme.
Jain KK
Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
[TBL] [Abstract][Full Text] [Related]
15. Implantable drug delivery devices (pumps, ports) in cancer therapy.
Ensminger WD; Wollner IS
Ration Drug Ther; 1988 May; 22(5):1-7. PubMed ID: 3045881
[No Abstract] [Full Text] [Related]
16. KS Biomedix licenses TransMID brain cancer product to Nycomed in European collaboration.
Expert Rev Anticancer Ther; 2002 Oct; 2(5):481. PubMed ID: 12382509
[No Abstract] [Full Text] [Related]
17. Brain tumor stem cells as research and treatment targets.
Hide T; Takezaki T; Nakamura H; Kuratsu J; Kondo T
Brain Tumor Pathol; 2008; 25(2):67-72. PubMed ID: 18987831
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization.
Elkharraz K; Faisant N; Guse C; Siepmann F; Arica-Yegin B; Oger JM; Gust R; Goepferich A; Benoit JP; Siepmann J
Int J Pharm; 2006 May; 314(2):127-36. PubMed ID: 16490330
[TBL] [Abstract][Full Text] [Related]
19. Experiences in vitro with cytostatic treatment.
Gazsó L
Minerva Neurochir; 1969; 13(3):257-9. PubMed ID: 5382576
[No Abstract] [Full Text] [Related]
20. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
Juillerat-Jeanneret L
Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
